Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 3/20 | 0.45 |
| ▸ | TRPC6 | Q9Y210 | 3/20 | 0.45 |
| ▸ | P4HTM | Q9NXG6 | 2/20 | 0.43 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | ECE1 | P42892 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ASPH | Q12797 | 1/20 | 0.40 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.40 |
| ▸ | XDH | P47989 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21045747 | 0.94 | TRPC6 (0.50) | KMOTRPC6P4HTMGPR35ALOX15 | |
| SCHEMBL29368707 | 0.86 | GPR35 (0.49) | KMOP4HTMGPR35ALOX15ECE1 | |
| SCHEMBL18009392 | 0.86 | GPR35 (0.49) | KMOP4HTMGPR35ALOX15ECE1 | |
| SCHEMBL72539 | 0.86 | TRPC6 (0.44) | TRPC6KDM4EL3MBTL1 | |
| SCHEMBL11894710 | 0.82 | KMO (0.46) | KMOP4HTMKDM4EASPHKDM8 | |
| SCHEMBL21045923 | 0.82 | TRPC6 (0.55) | KMOTRPC6P4HTMGPR35ALOX15 | |
| SCHEMBL21045922 | 0.82 | TRPC6 (0.55) | KMOTRPC6P4HTMGPR35ALOX15 | |
| SCHEMBL21045936 | 0.82 | TRPC6 (0.55) | KMOTRPC6P4HTMGPR35ALOX15 | |
| SCHEMBL21045707 | 0.82 | TRPC6 (0.57) | TRPC6MCL1 | |
| SCHEMBL72278 | 0.81 | MAPT (0.47) | TRPC6KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129537-B2 | Compounds as PDE IV and TNF inhibitors | RHONE-POULENC RORER LIMITED (GB) | 2012-03-06 | — | — | US | disclosed |
| US-20100240677-A1 | Compounds as PDE IV and TNF Inhibitors | AVENTIS PHARMA LIMITED (GB) | 2010-09-23 | — | — | US | disclosed |
| US-7652144-B2 | Compounds as PDE IV and TNF inhibitors | AVENTIS PHARMA LIMITED (GB) | 2010-01-26 | — | — | US | disclosed |
| US-7541466-B2 | Tetrahydroisoquinoline derivatives for treating protein trafficking diseases | GENZYME CORPORATION (US) | 2009-06-02 | — | — | US | disclosed |
| US-20080132706-A1 | Compounds as PDE IV and TNF Inhibitors | AVENTIS PHARMA LIMITED (GB) | 2008-06-05 | — | — | US | disclosed |
| US-7045660-B2 | Compounds as PDE IV and TNF-inhibitors | AVENTIS PHARMA LIMITED (GB) | 2006-05-16 | — | — | US | disclosed |
| US-20060084809-A1 | Compounds as PDE IV and TNF-inhibitors | AVENTIS PHARMA LIMITED (GB) | 2006-04-20 | — | — | US | disclosed |
| US-20050176761-A1 | Tetrahydroisoquinoline derivatives for treating protein trafficking diseases | GENZYME CORPORATION (US) | 2005-08-11 | — | — | US | disclosed |
| US-20040171618-A1 | Compounds as PDE IV and TNF-inhibitors | AVENTIS PHARMA LIMITED (GB) | 2004-09-02 | — | — | US | disclosed |
| US-20030013713-A1 | Compounds as PDE IV and TNF-inhibitors | FENTON GARRY (GB) | 2003-01-16 | — | — | US | disclosed |
| US-6472412-B1 | Compounds as PDE IV and TNF inhibitors | AVENTIS PHARMA LIMITED (GB) | 2002-10-29 | — | — | US | disclosed |
| EP-0711282-B1 | COMPOUNDS AS PDE IV AND TNF INHIBITORS | AVENTIS PHARMA LTD (GB) | 2002-06-05 | — | — | EP | disclosed |
| EP-0711282-A1 | COMPOUNDS AS PDE IV AND TNF INHIBITORS | RHONE-POULENC RORER LIMITED (GB) | 1996-05-15 | — | — | EP | disclosed |
| WO-1995004045-A1 | COMPOUNDS AS PDE IV AND TNF INHIBITORS | RHONE-POULENC RORER LIMITED (GB) | 1995-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084809-A1 | Compounds as PDE IV and TNF-inhibitors | PDE4A, PDE4B, PDE4C | KMO 1372/4885TRPC6 2523/4885P4HTM 1500/4885 |
| US-20030013713-A1 | Compounds as PDE IV and TNF-inhibitors | PDE4A, PDE4B, PDE7A | KMO 1087/4885TRPC6 2415/4885P4HTM 1284/4885 |
| US-20100240677-A1 | Compounds as PDE IV and TNF Inhibitors | PDE4A, PDE4B, PDE7A | KMO 1199/4885TRPC6 2515/4885P4HTM 1340/4885 |
| US-20080132706-A1 | Compounds as PDE IV and TNF Inhibitors | PDE4A, PDE4B, PDE7A | KMO 1199/4885TRPC6 2515/4885P4HTM 1340/4885 |
| US-20050176761-A1 | Tetrahydroisoquinoline derivatives for treating protein trafficking diseases | CFTR, NPC1L1, GOLT1B | KMO 4427/4885TRPC6 1018/4885P4HTM 1367/4885 |
| US-20040171618-A1 | Compounds as PDE IV and TNF-inhibitors | PDE4A, PDE4B, PDE7A | KMO 1087/4885TRPC6 2415/4885P4HTM 1284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.